We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...
Silexion Therapeutics reported 50% Tumor Reduction in Breakthrough Preclinical Systemic Administration Data; Maxim Group Analyst recently gave the company a Strong Buy Rating and a $9 Price...
Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for...
KRAS, one of the most mutated oncogenes across cancers, drives aggressive and treatment-resistant tumors. Silexion’s latest data highlights SIL-204’s ability to enhance first-line therapies...
Cayman Islands, January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...
Cayman Islands, January 15, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
Cayman Islands, January 13, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
Silexion Therapeutics (NASDAQ: SLXN) is advancing precision oncology with a focus on KRAS-driven cancers, among the most challenging targets in oncology. In collaboration with Evonik, Silexion...
Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
December 11, 2024 -- InvestorsHub NewsWire -- via PESG Research -- The field of precision oncology has witnessed groundbreaking advancements in recent years, and Silexion Therapeutics (NASDAQ:...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.465 | 218.656716418 | 0.67 | 3.45 | 0.575 | 141643094 | 2.38910861 | CS |
4 | 0.155 | 7.82828282828 | 1.98 | 3.45 | 0.575 | 34918576 | 2.34310182 | CS |
12 | -0.1807 | -7.80325603489 | 2.3157 | 4.23 | 0.575 | 15321943 | 2.52272275 | CS |
26 | -33.865 | -94.0694444444 | 36 | 36.36 | 0.575 | 8967221 | 3.3293385 | CS |
52 | -33.865 | -94.0694444444 | 36 | 36.36 | 0.575 | 8967221 | 3.3293385 | CS |
156 | -33.865 | -94.0694444444 | 36 | 36.36 | 0.575 | 8967221 | 3.3293385 | CS |
260 | -33.865 | -94.0694444444 | 36 | 36.36 | 0.575 | 8967221 | 3.3293385 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions